MEDXF (Medexus Pharmaceuticals) FFO


MEDXF Medexus Pharmaceuticals Inc MEDXF
60 GF Score
Price $3.62
GF Value $1.32
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

MEDXF
60GF Score
Medexus Pharmaceuticals Inc MEDXF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of $3.62 is trading 174.2% above its estimated GF Value™ of $1.32. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEDXF:

  • FFO:
  • GF Value™: $1.32 vs. price of $3.62 (174.2% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Other Exchanges P731:GermanyMDP:Canada
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
60GF Score

Get the complete analysis for MEDXF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.62
Price
$1.32
GF Value